Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Key Inclusion Criteria: * Histologically confirmed locally advanced or metastatic NSCLC which is EGFR wild-type, ALK rearrangement negative and METΔex14 mutated * No prior systemic therapy for advanced/metastatic disease (neo-adjuvant/adjuvant treatment completed \> 12 months before relapse are permitted) * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 * Measurable disease as per RECIST 1.1 * Known PD-L1 tumor expression status (applicable to Randomized part 2 only) Key Exclusion Criteria: * Prior treatment with a PD-1/PD-L1 inhibitor, MET inhibitor or HGF inhibitor * Presence of symptomatic CNS metastases or requiring local CNS-directed therapy (radiotherapy or surgery), or increasing doses of corticosteroids 2 weeks prior to study entry * Impaired cardiac function or clinically significant cardiac disease * Presence or history of interstitial lung disease, non-infectious pneumonitis or interstitial pneumonitis, including clinically significant radiation pneumonitis * History of allogenic bone marrow or solid organ transplant * Radiotherapy to lung fields ≤ 4 weeks or to any other anatomic site ≤ 2 weeks prior to start of study treatment (palliative radiotherapy for bone lesions is allowed)